Table 2. Results of the Base-Case Cost-Effectiveness Analyses Over a 5-Year Time Horizon From a Societal Perspective (Discounted) (EUR1.00 ≈ NOK7.47).
| Total costs (EUR) | Effects (QALYs) | Versus PD |
Sequential ICER (EUR/QALY) | |||
|---|---|---|---|---|---|---|
| Incremental cost (EUR) | Incremental effect (QALYs) | ICER (EUR/QALY) | ||||
| PD | 164,741 | 1.6825 | ||||
| HD home | 228,362 | 1.8613 | 63,621 | 0.1788 | 355,822 | 355,822 |
| Dominated strategies | ||||||
| HD hospital | 317,501 | 1.7169 | 152,760 | 0.0344 | 4,440,698 | Dominated by HD home |
| HD self-care | 261,260 | 1.7170 | 96,519 | 0.0344 | 2,805785 | Dominated by HD home |
| HD satellite | 352,048 | 1.7181 | 187,308 | 0.0356 | 5,261,461 | Dominated by HD home |
All HD strategies were compared to PD, because none of the more effective strategies were cost-effective compared to PD. QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio; INHB: incremental net health benefit; HD: hemodialysis; PD: peritoneal dialysis.